China Pharma Holdings (CPHI) Current Leases (2019 - 2026)
China Pharma Holdings (CPHI) posted Current Leases of $71386.0 for Q1 2026, little changed on a QoQ basis from $71628.0 in Q4 2025, and up 260.97% year-over-year from $19776.0 in Q1 2025.
China Pharma Holdings (CPHI) Current Leases (2019 - 2026) Analysis & Trends
China Pharma Holdings' Current Leases history runs 8 years deep, the most recent figure standing at $71386.0 for Q1 2026.
- Quarterly Current Leases rose 260.97% year-over-year to $71386.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71386.0 (up 260.97% YoY) and the FY2025 annual result came in at $71628.0, up 82.15% from the prior year.
- Current Leases was $71386.0 for Q1 2026 at China Pharma Holdings, roughly flat from $71628.0 in the prior quarter.
- Across five years, Current Leases topped out at $86672.0 in Q1 2022 and bottomed at $19776.0 in Q1 2025.
- A 5-year average of $63001.6 and a median of $71507.0 in 2025 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2023 — Current Leases sank 76.21% — and 2024, when it jumped 279.71%.
- China Pharma Holdings' Current Leases stood at $40445.0 in 2022, then soared by 92.18% to $77727.0 in 2023, then slumped by 49.41% to $39323.0 in 2024, then soared by 82.15% to $71628.0 in 2025, then fell by 0.34% to $71386.0 in 2026.
- Business Quant data shows CPHI's Current Leases at $71386.0 in Q1 2026, $71628.0 in Q4 2025, and $70326.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | 71,386.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 71,386.00 |
| Dec 31, 2025 | 71,628.00 |
| Sep 30, 2025 | 70,326.00 |
| Mar 31, 2025 | 19,776.00 |
| Dec 31, 2024 | 39,323.00 |
| Sep 30, 2024 | 60,241.00 |
| Jun 30, 2024 | 78,628.00 |
| Mar 31, 2024 | 78,284.00 |
| Dec 31, 2023 | 77,727.00 |
| Sep 30, 2023 | 76,000.00 |
| Jun 30, 2023 | 74,850.00 |
| Mar 31, 2023 | 20,617.00 |
| Dec 31, 2022 | 40,445.00 |
| Sep 30, 2022 | 59,163.00 |
| Jun 30, 2022 | 82,959.00 |
| Mar 31, 2022 | 86,672.00 |
| Dec 31, 2021 | 85,282.00 |
| Sep 30, 2021 | 82,851.00 |
| Jun 30, 2021 | 83,707.00 |
| Mar 31, 2021 | 26,743.00 |